We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Kapa Biosystems and VWR International Sign Agreement
News

Kapa Biosystems and VWR International Sign Agreement

Kapa Biosystems and VWR International Sign Agreement
News

Kapa Biosystems and VWR International Sign Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Kapa Biosystems and VWR International Sign Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Kapa Biosystems and VWR International, LLC announced that they have entered into a non-exclusive North American distribution agreement for Kapa Biosystems' line of next-generation PCR reagents.

Kapa Biosystems employs a high-throughput molecular evolution technology platform to engineer DNA-modifying enzymes for applications in DNA amplification, next-generation sequencing, and molecular diagnostics.

Under the terms of the agreement, VWR has the rights to distribute Kapa Biosystems' portfolio of products for applications such as high fidelity PCR, fast PCR, long range PCR, whole blood PCR, crude sample PCR, and single protocol PCR.

VWR, a global laboratory supply and distribution company with worldwide sales in excess of $3.7 billion in 2008, enables the advancement of the world’s most critical research through the distribution of a highly diversified product line to most of the top pharmaceutical and biotech companies, as well as industrial, educational and governmental organizations.

“Kapa Biosystems' high performance PCR reagents allow researchers to consolidate protocols, simplify workflows, save time, and achieve results not possible with reagents based on wild-type enzymes.”

"Kapa Biosystems' high performance PCR reagents allow researchers to consolidate protocols, simplify workflows, save time, and achieve results not possible with reagents based on wild-type enzymes," said Ron McEwan, CEO of Kapa Biosystems. "Kapa's agreement with VWR will significantly expand our ability to offer the benefits of these novel products to the broader life sciences research community."

The DNA polymerases contained in Kapa Biosystems' reagents have been engineered through a process of molecular evolution and possess amino acid modifications that confer improvements to the function of the enzymes.
Advertisement